We know gout is among the many comorbidities that increase the risk of cardiovascular disease (CVD). In 2018, the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial concluded that febuxostat was non-inferior to allopurinol. BUT, two of the secondary endpoints were very concerning. Febuxostat was inferior to allopurinol in terms of cardiovascular death and all-cause mortality. Many clinicians were left wondering whether febuxostat was cardiotoxic …. or conversely, perhaps allopurinol was cardioprotective. Will another cardiovascular outcome trial provide greater clarity to guide clinical practice?
Guest Authors: Sophia Dietrich, PharmD and Michael W. Nagy, PharmD, BCACP
Guest Panelist: Dawn Fuke, PharmD, BCPS
Music by Good Talk
D-PRESCRIBE Study: As Age Goes Up, The Medication Must Go Down!
Keeping Intensive Blood Pressure Goals in MIND: Does it Impact Cognitive Decline?
Is a Team-Based Approach in Primary Care Worth It?
Cardiovascular Risk with Elevated Triglycerides - Does Icosapent Ethyl REDUCE-IT?
Another Case of Newer Isn’t Always Better! Gabapentin vs. Pregabalin for Chronic Sciatica
Fall Risk and Benzos – Is Trazodone Really the Knight in Shining Armor?
Top Ten Things Every Clinician Should Know About the 2018 Cholesterol Guidelines
Another Attempt to ARRIVE at an Answer Using Aspirin for Primary Prevention
Does a “One-Size-Fits-All” Aspirin Dosing Approach Still Hold WEIGHT?
Aspirin for Primary Prevention of CV Events in Diabetes - Is the Evidence ASCENDing?
LDL Limbo: How Low is Too Low?
Top Ten Things Every Clinician Should Know About the 2018 Antithrombotic Therapy Atrial Fibrillation Guidelines
Maybe Old is Gold? Newer Insulins Might Not Be Better – Just More Expensive
Using Controllers PRN for Mild Persistent Asthma – An Oxymoron?
The ZOE Trials – The Herpes Zoster Recombinant Subunit Vaccine — It’s Time to Upgrade!
Are You REAL-ly Paying Attention? The Importance of Attention Controls
Is it Time to “Step Up” Rescue Treatment for Asthma to Prevent Exacerbations?
Stop the Shots: Edoxaban vs Dalteparin in Cancer-Associated VTE Treatment
Hypertension – Time for Patients to Control the Wheel
Cutting Down HIV Treatment to a 2-Drug Regimen
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
Well Beyond Medicine: The Nemours Children’s Health Podcast